-
公开(公告)号：US09952226B2
公开(公告)日：2018-04-24
申请号：US15357841
申请日：2016-11-21
发明人： Abdolamir Landi , Michael Houghton , D. Lorne Tyrrell , Tim Lankisch , Tobias Weismueller , Michael Manns
IPC分类号： A61K39/395 , G01N33/68 , A61K45/00
CPC分类号： G01N33/6893 , A61K45/00 , G01N33/6827 , G01N2333/521 , G01N2333/523 , G01N2333/5443 , G01N2333/916 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , G16H50/30 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
-
公开(公告)号：US20150219664A1
公开(公告)日：2015-08-06
申请号：US14423998
申请日：2013-09-06
CPC分类号： G01N33/6893 , A61K45/00 , G01N33/6827 , G01N2333/521 , G01N2333/523 , G01N2333/5443 , G01N2333/916 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , G16H50/30 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
摘要翻译： 本公开提供了用于促进受试者中炎症性肝病诊断的方法和组合物。 方法和组合物通常涉及单独或与嗜酸细胞活化趋化因子-1（E1）水平以及任选地与CCL22水平以及进一步任选的IL15水平检测嗜酸细胞活化趋化因子-3（E3）水平。 这些水平可以用于促进自身免疫性肝炎（AIH），原发性胆汁性肝硬化（PBC）和原发性硬化性胆管炎（PSC）中的至少一种的肝脏疾病的诊断，和/或促进AIH， PBC和PSC。 本公开的方法和组合物还用于促进受试者的治疗决定。
-
公开(公告)号：US20180209992A1
公开(公告)日：2018-07-26
申请号：US15922012
申请日：2018-03-15
发明人： Abdolamir Landi , Michael Houghton , D. Lorne Tyrrell , Tim Lankisch , Tobias Weismueller , Michael Manns
CPC分类号： G01N33/6893 , A61K45/00 , G01N33/6827 , G01N2333/521 , G01N2333/523 , G01N2333/5443 , G01N2333/916 , G01N2800/085 , G16B40/00 , G16H50/20 , G16H50/30 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
-
公开(公告)号：US20170153251A1
公开(公告)日：2017-06-01
申请号：US15357841
申请日：2016-11-21
发明人： Abdolamir Landi , Michael Houghton , D. Lorne Tyrrell , Tim Lankisch , Tobias Weismueller , Michael Manns
CPC分类号： G01N33/6893 , A61K45/00 , G01N33/6827 , G01N2333/521 , G01N2333/523 , G01N2333/5443 , G01N2333/916 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , G16H50/30 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
-
公开(公告)号：US09535071B2
公开(公告)日：2017-01-03
申请号：US14423998
申请日：2013-09-06
发明人： Abdolamir Landi , Michael Houghton , D. Lorne Tyrrell , Tim Lankisch , Tobias Weismueller , Michael Manns
CPC分类号： G01N33/6893 , A61K45/00 , G01N33/6827 , G01N2333/521 , G01N2333/523 , G01N2333/5443 , G01N2333/916 , G01N2800/085 , G06F19/00 , G06F19/24 , G16H50/20 , G16H50/30 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.
摘要翻译： 本公开提供了用于促进受试者中炎症性肝病诊断的方法和组合物。 方法和组合物通常涉及单独或与嗜酸细胞活化趋化因子-1（E1）水平以及任选地与CCL22水平以及进一步任选的IL15水平检测嗜酸细胞活化趋化因子-3（E3）水平。 这些水平可以用于促进自身免疫性肝炎（AIH），原发性胆汁性肝硬化（PBC）和原发性硬化性胆管炎（PSC）中的至少一种的肝脏疾病的诊断，和/或促进AIH， PBC和PSC。 本公开的方法和组合物还用于促进受试者的治疗决定。
-
-
-
-
搜索结果
5 条记录 (耗时 0.028 秒)
